The Joshua Frase Foundation for Congenital Myopathy Research Inc (EIN 597059890) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1996

Legal Domicile

Principal Officer

Alison Rockett

Phone

9048214246

Tax Period

2023-01-01 to 2023-12-31

The Joshua Frase Foundation for Congenital Myopathy Research Inc, founded in 1996, is a micro nonprofit in the Diseases & Disorders sector that reported $51K in total revenue in fiscal year 2023. Revenue fell 24% from the prior year — a significant decline worth monitoring. Expenses of $88K exceeded revenue, resulting in a 71% operating deficit.

Mission

Research for Myotubular Myopathy and other Congenital Myopathies, educational information, and research support.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $51,221

Program Service Revenue $0

Investment Income $50

Other Revenue $0

TOTAL REVENUE $51,271

Expense Breakdown

Grants Paid $1,897

Salaries & Benefits $59,051

Fundraising Expenses $31,203

Program Expenses $43,747

Other Expenses $26,904

TOTAL EXPENSES $87,852

Year-over-Year Comparison

	2023	2022	Change
Revenue	$51,271	$67,138	-0.2%
Expenses	$87,852	$89,704	0.0%
Net Income	$-36,581	$-22,566	+0.6%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$54,855

Total Directors

$54,855

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Alison Rockett	President	55.00	Officer Director	$54,855	$0	$54,855
Lisa Nickerson	Vice president	1.00	Officer Director	$0	$0	$0
Paul Frase	Secretary	1.00	Officer Director	$0	$0	$0
Scott Grant	Director	1.00	Director	$0	$0	$0
Sean Klinkowize	Director	1.00	Director	$0	$0	$0
Daryl Johnston	Director	1.00	Director	$0	$0	$0
Angelica Townshend	Director	1.00	Director	$0	$0	$0
Edward Costa	Director	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$51,271	$87,852	$47,901	$-36,581
2022	$67,138	$89,704	$75,171	$-22,566
2021	$213,958	$155,324	$93,224	$58,634
2020	$67,348	$149,492	$49,428	$-82,144
2019	$85,200	$154,269	$128,020	$-69,069
2018	$184,667	$131,560	$182,211	$53,107

The Joshua Frase Foundation for Congenital Myopathy Research Inc